Biopharma AI
By
Is Eli Lilly’s $1.3B Acquisition of Verve the Turning Point for CRISPR-Based Cardiovascular Therapies?
Key Highlights Strategic Bet on Early-Stage InnovationEli Lilly’s acquisition of Verve Therapeutics for up to $1.3 billion marks…
Is HEALWELL AI’s Acquisition of BioPharma Canada’s Biggest AI-Driven CRO Leap Yet—and a Blueprint for Future Clinical Trials?
Key Highlights HEALWELL Targets AI-Driven Scale in CRO with $14.4M BioPharma AcquisitionHEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)…
How Merck’s $3B MoonLake Acquisition the AI-Powered Bet That Will Reignite Late-Phase Biotech and Immune-Driven Precision Trials?
Key Highlights Merck Moves Decisively: A $3 Billion Signal to the Late-Stage Biotech MarketMerck has reportedly offered over…
Can HekaBio and Alfresa’s AI-Driven Alliance Redefine Japan’s Biopharma Access and Launch Asia’s Next AI Commercialization Engine?
Smart Partnerships: HekaBio Leverages Alfresa’s Scale to Localize Global InnovationJapan’s historically delayed access to global therapies may soon…
Can Revolution Medicines and Iambic’s AI Alliance Accelerate the Discovery of Next-Gen Cancer Drugs Targeting RAS Mutations?
Key Highlights AI-Powered Discovery for RAS-Addicted CancersRevolution Medicines, a leader in targeting RAS-driven cancers, is turning to artificial…
Can Johnson & Johnson’s 6-Point AI Strategy Revolutionize Surgery, Drug Discovery, and Global Patient Care?
Key Highlights From Experimentation to Execution: Focused AI for Measurable OutcomesAfter piloting 900+ generative AI use cases, Johnson…
